Checkmate Pharmaceuticals (CMPI) Stock Analysis

What Checkmate Pharmaceuticals does

Checkmate Pharmaceuticals, Inc. is a biotechnology company focused on the clinical development of innovative cancer treatments. Its primary therapeutic candidate, CMP-001, is undergoing Phase II clinical trials. This investigational drug is being evaluated in combination with pembrolizumab for patients with melanoma resistant to PD-1 inhibitors, and alongside nivolumab for PD-1-naïve neoadjuvant melanoma. The company maintains strategic collaborations with pharmaceutical giants Merck KGaA and Pfizer. Established in 2015, its corporate headquarters are located in Cambridge, Massachusetts. Since May 27, 2022, Checkmate Pharmaceuticals, Inc. has operated as a subsidiary of Regeneron Pharmaceuticals, Inc.

Key metrics

ETFs linked to CMPI

Broad-market and Healthcare sector ETFs an investor holding Checkmate Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CMPI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals trades under the ticker CMPI on NASDAQ.

Which exchange is CMPI listed on?

CMPI is listed on NASDAQ.

What sector does Checkmate Pharmaceuticals operate in?

Checkmate Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CMPI in a portfolio?

PortView shows CMPI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.